I don't think it's going to be a straightforward answer, which is why no one has really figured this out, and we need a lot of data and a lot of touch points with a patient
Confusing the two can lead to disappointed patients and administrative headaches for your practice
This review explains upfront costs, inclusions, guarantee terms, dose pricing, official price conflicts, and changes since Mira's previous review
[1] [2] While there is no definitive evidence of this risk in humans, patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications
At present, the most defensible conclusion is implementation-oriented rather than economic: access, reimbursement, equity, and opportunity cost are likely to shape uptake more strongly than efficacy alone (204, 205)
It is unknown whether Saxenda causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined